文献速递银屑病与炎症性皮肤病

基于荷兰BioCAPTURE十年真实世界证据的斑块状银屑病生物制剂治疗序列成本效用分析

Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE.
PubMed 文献 · Br J Dermatol · 2018-03-01

该研究基于荷兰BioCAPTURE注册登记10年真实世界证据,构建序列模型评估三种生物制剂连续治疗线(如阿达木单抗-依那西普-乌司奴单抗 vs. 依那西普-乌司奴单抗-阿达木单抗)在荷兰10年时间范围内的成本与健康效果。起始使用阿达木单抗或乌司奴单抗在成本和效用方面似乎优于起始使用依那西普,但可信区间部分重叠。结论认为生物制剂使用顺序影响成本效果,起始治疗可能以阿达木单抗或乌司奴单抗为佳,依那西普从健康经济学角度似乎不太理想。

要点

  • 生物制剂使用顺序影响银屑病治疗的成本效果,包括成本和健康效果两方面。
  • 起始使用阿达木单抗或乌司奴单抗在成本和效用方面似乎优于起始使用依那西普。

核心结论

  • 生物制剂的使用顺序影响治疗的成本效果,包括成本和健康效果两方面。
  • 起始生物制剂治疗序列可能最好使用阿达木单抗或乌司奴单抗;依那西普从健康经济学角度似乎不太理想。

研究设计与样本

  • 开发序列模型评估三种连续生物制剂治疗线的成本和健康效果,时间范围为荷兰10年。
  • 模型数据来自荷兰BioCAPTURE注册登记和科学文献。
  • 分析每质量调整生命年(QALY)成本,并通过概率分析和情景分析处理不确定性。

主要发现

  • 起始使用阿达木单抗或乌司奴单抗在成本和效用方面似乎优于起始使用依那西普,但可信区间部分重叠。

临床怎么用

  • 起始生物制剂治疗序列时可能优先考虑阿达木单抗或乌司奴单抗。
  • 从健康经济学角度,依那西普作为起始生物制剂似乎不太理想。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment with biologics may be indicated for patients with moderate-to-severe plaque psoriasis, but comparative evidence on cost-effectiveness is limited. Switching of biologics is common, but it is unclear what the effect is of differences in sequences of biologics. OBJECTIVES: To evaluate the cost-effectiveness of different biologic treatment sequences for psoriasis based on real-world evidence. PATIENTS AND METHODS: A sequence model was developed to evaluate the costs and health effects of three consecutive lines of biologic treatments [for example adalimumab-etanercept-ustekinumab (Ada-Eta-Ust) vs. Eta-Ust-Ada] over a 10-year time horizon in the Netherlands. The model was populated with data from the Dutch BioCAPTURE registry and scientific literature. Analyses were conducted of cost per quality-adjusted life year (QALY) and uncertainty was addressed by probabilistic as well as scenario analyses. RESULTS: Treatment of psoriasis with biologics for a 10-year period was estimated to be associated with a cost of €141 962 to €148 442 per patient depending on the treatment sequence used. Cumulative health effects ranged from 7·79 to 8·03 QALYs. Starting with Ada or Ust seems favourable concerning cost and utilities compared with strategies starting with Eta, although credible intervals were partly overlapping. CONCLUSIONS: The order in which biologics are used influences treatment cost-effectiveness, both in terms of costs and health effects. Initiation of a biologic treatment sequence for psoriasis might best be done with Ada or Ust; Eta seems less optimal from a health-economic perspective.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Klijn SL, van den Reek JMPA, van de Wetering G, et al. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE. Br J Dermatol. 2018. PMID: 29247500. doi:10.1111/bjd.16247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。